U.S. National Library of MedicineNational Institutes of Health
Skip navigation
MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You
  FAQs Site Map About MedelinePlus Contact Us
español
HealthDay Logo

Two-Drug Combo May Lower Diabetics' Kidney Risk

A pair of blood pressure medicines helps maintain proper organ function, study suggests
Printer-friendly version E-mail this page to a friend

HealthDay

By Robert Preidt

Thursday, February 19, 2009

HealthDay news imageTHURSDAY, Feb. 19 (HealthDay News) -- A combination of two blood pressure-lowering drugs reduced the risk of kidney disease by about 20 percent in people with type 2 diabetes, according to researchers who analyzed data from a study that included more than 11,000 patients.

The patients were randomly selected to receive either placebos or a combination of the angiotensin-converting enzyme (ACE) inhibitor perindopril and the diuretic indapamide. Most of the patients had high blood pressure, but 20 percent had normal blood pressure -- less than 130/80 mm Hg.

After an average follow-up of four years, patients taking the blood pressure-lowering drugs were 21 percent less likely to have kidney disease than those in the placebo group. The researchers also found that kidney function returned to normal among some patients who had early signs of diabetes-related kidney disease before they started taking the drugs.

Even in patients who didn't have high blood pressure, the drug combination reduced the risk of kidney disease.

More research is needed, but these results suggest that patients with type 2 diabetes might be considered for antihypertensive treatment even if they have normal blood pressure, said the authors of the study, which appears in the April issue of the Journal of the American Society of Nephrology.

The researchers noted their study did have important limitations, including the fact that it was an analysis of a previous clinical trail.

"Most of the findings related to early manifestation of kidney disease [albuminuria], and the study was not large enough to assess the impact of the intervention directly on the risk of kidney failure. We could not separate out the impact of the blood pressure-lowering combination used, or prove whether it had any effects beyond its blood pressure-lowering effects," study co-author Vlado Perkovic, of the George Institute for International Health in Sydney, Australia, added in an American Society of Nephrology news release.


HealthDay

Copyright (c) 2009 ScoutNews, LLC. All rights reserved.

Related News:
More News on this Date

Related MedlinePlus Pages: